Sun Pharma Global recalls osteoporosis drug in US

Published: 15-Mar-2016
Regulatory

After an 'unknown purity' was discovered in cartons of alendronate sodium tablets


Around 380,000 cartons of an osteoporosis drug manufactured by Sun Pharmaceutical Industries are being recalled in the US due to the presence of an 'unknown impurity'.

Sun Pharma Global Fze, an arm of the Indian pharma major, has decided to recall 381,120 cartons of alendronate sodium tablets, which are indicated for the treatment and prevention of osteoporosis in post menopausal women, and to increase bone mass in men with osteoporosis.

The drug is also used in the treatment of glucocorticoid induced osteoporosis, and Paget’s disease of the bone in men and women.

  • Companies:
  • Sun Pharmaceutical Industries
See more

You may also like

Regulatory

Several large Indian pharma companies under US FDA scrutiny

Read more
Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories

Trending Articles

  1. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  2. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  3. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  4. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  5. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Several large Indian pharma companies under US FDA scrutiny

Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Regulatory

US FDA says Ranbaxy has to forfeit exclusivity for capsules to treat stomach and aesophagus problems

US regulator revokes tentative approvals for two Ranbaxy generics
Regulatory

US FDA to continue to target non-compliant Indian companies

All available enforcement tools to be utilised to bring facilities to compliance to ensure the protection of public health
Media

Bureaucracy is impeding India\'s growth in pharma, says report

Strong commercial opportunities suffering because of government policy, according to latest Business Monitor report
Manufacturing

FDA prohibits manufacture of FDA-regulated drugs from Ranbaxy plant in Mohali

Agency issues import alert and adds this facility to existing consent decree until such time as company complies with cGMP
Regulatory

Indian manufacturers challenge Drug Price Control Order

Move could delay the introduction of low priced medicines in the market
Regulatory

Intellectual property battles rage on

Spate of cases filed recently shows that patent battles are heating up
Subscribe now